Characteristic | Partial R | p |
---|---|---|
Age at time of study | 0.175 | 0.03 |
Age at RA onset | −0.011 | 0.9 |
Women | 0.079 | 0.3 |
Traditional cardiovascular risk factors | ||
Any risk factors | 0.021 | 0.8 |
Hypertension | 0.079 | 0.3 |
Dyslipidemia | 0.038 | 0.7 |
Smoking | 0.108 | 0.2 |
Diabetes | 0.032 | 0.7 |
Obesity | −0.218 | 0.01 |
No. risk factors | 0.023 | 0.8 |
Body mass index | −0.277 | 0.0009 |
Blood pressure | ||
Systolic | 0.049 | 0.8 |
Diastolic | 0.035 | 0.7 |
Lipid variables | ||
Total cholesterol | 0.060 | 0.5 |
LDL cholesterol | −0.068 | 0.4 |
HDL cholesterola | 0.074 | 0.4 |
Total-HDL cholesterol ratio | −0.060 | 0.5 |
Triglyceridesa | 0.142 | 0.1 |
Triglycerides/HDL cholesterol ratioa | 0.085 | 0.3 |
Chronic kidney disease | 0.019 | 0.8 |
Cardiovascular drugs | ||
Antihypertensives | 0.079 | 0.3 |
Statins | 0.073 | 0.4 |
Glucose lowering agents | ||
Any | 0.034 | 0.7 |
Oral hypoglycemic agents | −0.014 | 0.9 |
Insulin | −0.007 | 0.9 |
RA disease durationa | 0.131 | 0.1 |
RF-positive | 0.323 | < 0.0001 |
Anti-CCP–positive | 0.217 | 0.008 |
Extraarticular manifestation(s) | 0.091 | 0.3 |
Joint erosion(s) in hands or/and feet | 0.159 | 0.05 |
C-reactive proteina | 0.123 | 0.1 |
Erythrocyte sedimentation ratea | 0.067 | 0.4 |
Disease Activity Score in 28 joints | −0.017 | 0.9 |
Antirheumatic agents | ||
Any DMARD | 0.046 | 0.6 |
Synthetic DMARD | ||
Any | 0.013 | 0.9 |
Methotrexate | −0.030 | 0.7 |
Chloroquine | 0.117 | 0.2 |
Leflunomide | 0.030 | 0.7 |
Sulfasalazine | 0.132 | 0.1 |
No. | 0.106 | 0.2 |
Biologic DMARD | ||
Any | 0.023 | 0.8 |
TNF-α inhibitor | 0.040 | 0.6 |
Non TNF-α inhibitor | 0.063 | 0.5 |
Prednisone | 0.084 | 0.3 |
↵a Logarithmically transformed. OPG: osteoprotegerin; RA: rheumatoid arthritis; LDL: low-density lipoprotein; HDL: high-density lipoprotein; CCP: cyclic citrullinated peptide antibody; DMARD: disease-modifying antirheumatic drug; TNF-α: tumor necrosis factor-α; RF: rheumatoid factor.